These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25850606)

  • 1. Implementation and Operational Research: Effects of CD4 Monitoring Frequency on Clinical End Points in Clinically Stable HIV-Infected Patients With Viral Suppression.
    Ahn JY; Boettiger D; Law M; Kumarasamy N; Yunihastuti E; Chaiwarith R; Lee MP; Sim BL; Oka S; Wong W; Kamarulzaman A; Kantipong P; Phanuphak P; Ng OT; Kiertiburanakul S; Zhang F; Pujari S; Ditangco R; Ratanasuwan W; Merati TP; Saphonn V; Sohn AH; Choi JY;
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):e85-92. PubMed ID: 25850606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.
    Wright ST; Carr A; Woolley I; Giles M; Hoy J; Cooper DA; Law MG;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):72-9. PubMed ID: 21654498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression.
    Gianotti N; Marchetti G; Antinori A; Saracino A; Gori A; Rizzardini G; Lichtner M; Bandera A; Mussini C; Girardi E; dʼArminio Monforte A; Cozzi-Lepri A
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):417-422. PubMed ID: 28816721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
    De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine CD4 monitoring in HIV patients with viral suppression: Is it really necessary? A Portuguese cohort.
    Duro R; Rocha-Pereira N; Figueiredo C; Piñeiro C; Caldas C; Serrão R; Sarmento A
    J Microbiol Immunol Infect; 2018 Oct; 51(5):593-597. PubMed ID: 28712820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
    Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
    AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Nicolás D; Esteve A; Cuadros A; Campbell CNJ; Tural C; Podzamczer D; Murillas J; Homar F; Segura F; Force L; Vilaró J; Masabeu À; Garcia I; Mercadal J; Montoliu A; Ferrer E; Riera M; Cifuentes C; Ambrosioni J; Navarro G; Manzardo C; Clotet B; Gatell JM; Casabona J; Miró JM; ; Murillas J; Manzardo C; Masabeu A; Mercadal J; Cifuentes C; Dalmau D; Domingo P; Falcó V; Curran A; Agustí C; Montoliu A; Pérez I; Curto J; Gargoulas F; Gómez A; Rubia JC; Zamora L; Blanco JL; Garcia-Alcaide F; Martínez E; Mallolas J; Llibre JM; Sirera G; Romeu J; Jou A; Negredo E; Saumoy M; Imaz A; Bolao F; Cabellos C; Peña C; DiYacovo S; Van Den Eynde E; Sala M; Cervantes M; Amengual MJ; Navarro M; Segura V; Barrufet P; Molina J; Alvaro M; Payeras T; Gracia Mateo M; Fernández J
    Clin Infect Dis; 2016 Jun; 62(12):1578-1585. PubMed ID: 27126346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
    Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
    Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine CD4 cell count monitoring seldom contributes to clinical decision-making on antiretroviral therapy in virologically suppressed HIV-infected patients.
    Chow EP; Read TR; Chen MY; Fehler G; Bradshaw CS; Fairley CK
    HIV Med; 2015 Mar; 16(3):196-200. PubMed ID: 25236189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.